Vumerity Capsule
Product Images NDC 64406-020

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Vumerity (NDC 64406-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vum01 0006 01

Chemical structure of diroximel fumarate, the active ingredient in Vumerity capsules. The diagram shows the molecular arrangement including functional groups such as ester and amide linkages.*

FDA Label Image

Vum01 0006 02

A Kaplan-Meier curve showing the percentage of subjects with confirmed progression of disability over 96 weeks. The x-axis represents time on study in weeks, and the y-axis shows the percentage of subjects. Two lines compare Placebo (408 subjects) and Dimethyl Fumarate (DMF) 240 mg BID (409 subjects), with final progression rates of 27.1% for Placebo and 16.4% for DMF. Confirmed progression is defined by a specified increase in EDSS score sustained for 12 weeks.*

FDA Label Image

Vum01 0006 03

Vumerity 231 mg delayed-release capsules packaging label shows a starter dose bottle containing 106 capsules. The label lists the active ingredient as diroximel fumarate and includes storage instructions and prescribing information references. It is manufactured by Biogen Inc. and includes contact information and a barcode.*

FDA Label Image

Vum01 0006 04

Vumerity 231 mg delayed-release capsules label showing this is a starter dose bottle containing 106 capsules. The label highlights the active ingredient diroximel fumarate and includes storage instructions along with manufacturer Biogen Inc. Contact information and NDC 64406-020-01 are also visible.*

FDA Label Image

Vum01 0006 05

Packaging label for Vumerity 231 mg delayed-release capsules by Biogen Inc., containing 120 capsules. The label displays the proprietary name Vumerity and the generic name diroximel fumarate. It specifies maintenance dose bottle, RX only, and includes storage instructions and manufacturer details. NDC 64406-020-03 is visible.*

FDA Label Image

Vum01 0006 06

Label of Vumerity 231 mg delayed-release capsules by Biogen Inc. This label is for a maintenance dose bottle containing 120 capsules. It includes storage instructions, manufacturer information, and a note to see prescribing information for dosage and administration details.*

FDA Label Image

Vum01 0006 07

Carton packaging label for Vumerity 231 mg delayed-release capsules containing diroximel fumarate. The label indicates a count of 106 capsules. It shows the product is Rx only, manufactured for Biogen Inc., and includes storage instructions and barcodes. The label design features blue, gray, and white colors with the Biogen logo.*

FDA Label Image

Vum01 0006 08

Label for Vumerity (diroximel fumarate) delayed-release capsules, 231 mg strength. The label indicates the package contains 106 capsules. Manufactured for Biogen Inc., with storage instructions between 20°C to 25°C. Includes contact information and a note to see prescribing information for dosage and administration. NDC 64406-020-05 is shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.